


Lytix Biopharma Email Formats
Biotechnology Research • Oslo, Oslo, Norway • 21-50 Employees
Lytix Biopharma Email Formats
Lytix Biopharma uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@lytixbiopharma.com), used 75% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@lytixbiopharma.com | 75% |
{first initial}.{last name} | j.doe@lytixbiopharma.com | 25% |
Key Contacts at Lytix Biopharma
Claus Andersson
Member Of The Board Of Directors
Julie Dehaene-Puype
Non Executive Director
Øystein Rekdal
Chief Executive Officer
Mette Husbyn
Chief Technology Officer
John S. Svendsen
Director Discovery Research
Gunnar Slid
Ceo
Company overview
| Headquarters | Sandakerveien 138, Oslo, 0484, NO |
| Phone number | +4777675500 |
| Website | |
| SIC | 283 |
| Founded | 2003 |
| Employees | 21-50 |
| Socials |
About Lytix Biopharma
Lytix Biopharma is a clinical-stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. Lead compound LTX-315 provides access to antigens by using the patient’s own tumor as source of antigens and turns cold tumors hot. Local treatment with LTX-315 targets the first step in the cancer immunity cycle with a potential cornerstone position in immunotherapy.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Lytix Biopharma has 6 employees across 4 departments.
Departments
Number of employees
Funding Data
Explore Lytix Biopharma's funding history, including investment rounds, total capital raised, and key backers.
Lytix Biopharma Tech Stack
Discover the technologies and tools that power Lytix Biopharma's digital infrastructure, from frameworks to analytics platforms.
Security
Video players
Cookie compliance
JavaScript libraries
Maps
UI frameworks
JavaScript libraries
CDN
JavaScript libraries
Programming languages
UI frameworks
Frequently asked questions
4.8
40,000 users



